procedure was stopped.
The information was relayed to the National Organ Distribution Center. Detailed pathological examination of the non-transplanted kidney revealed papillary renal cell carcinoma ( Figure 2 ). Renal cell carcinoma, although rare, may be observed during kidney harvesting for cadaveric organ transplantation. This incidence is reported as 0.9% (1). Serralta et al. (4) reported that they did not observe tumor transfer in the follow-up of 49 months in 6 recipients who received liver transplants from cadaveric donors known to have earlystage renal cell carcinoma (T1 to T2) and early prostate carcinoma (T1). On the other hand, it has been reported in a study that 117 in 270 recipients receiving transplants from donors with known malignancy, showed tumoral development (3). Sack et al. (6) reported that a patient who had undergone a heart transplant from a donor with hypernephroma developed a malignant tumor with the same characteristics as hypernephroma. Current opinion recommends avoidance of organ transplantation from donors with malignancy, excluding low-grade skin neoplasms, in situ carcinoma of organs like the uterus, cervix and certain primary brain tumors (3). Before organ transplantation with a cadaveric donor, despite the donor having no known disease history, consideration of an easily available imaging technique such as ultrasonography in order to rule out the possibility of a renal cell carcinoma ultrasonography is recommended. 
